Type Size

    Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.

    79 adults with osteogenesis imperfecta were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The authors found that adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength.

    Read Article